Coordinating and Data Sharing Center - R&D of Vaccines and Antibodies for Pandemic Preparedness (ReVAMPP)

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 1UG3AI181797-01

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2024
    2027
  • Known Financial Commitments (USD)

    $7,994,888
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    PROGRAM DIRECTOR Sean Hanlon
  • Research Location

    United States of America
  • Lead Research Institution

    RESEARCH TRIANGLE INSTITUTE
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Therapeutics logistics and supply chains and distribution strategies

  • Special Interest Tags

    Data Management and Data Sharing

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

0BPROJECT SUMMARY/ABSTRACT The global pandemic caused by SARS-CoV-2 highlighted the continual threat of emerging and re-emerging pandemic-potential pathogens and the critical value of coordinated multidisciplinary basic and translational research for pandemic preparedness. There is an urgent need for an integrated collaborative effort to build a robust basic research and translational science portfolio for preparedness against high-risk viral families including Paramyxoviridae, Picornaviridae, and Bunyavirales. The National Institute of Allergy and Infectious Diseases (NIAID) is supporting the development of the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network to fill this critical gap. The overall goal of this new collaborative Network, consisting of a Coordinating and Data Sharing Center (CDSC) and six to eight Research Centers, is to collaboratively produce generalizable knowledge that enables a rapid response when previously understudied or unknown pathogens emerge. RTI International's well-established track record implementing large-scale domestic and international coordinating and data management centers, including in the emerging infectious disease ecosystem, makes us well qualified to develop and provide Network governance, communications, and data sharing and analysis as the ReVAMPP CDSC. The overall goal of the RTI-based CDSC is to establish and maintain an integrated Network to accelerate discovery and dissemination of novel vaccine and monoclonal antibody strategies to prepare for the next pandemic outbreak. To accomplish this goal, RTI proposes a CDSC organizational structure, consisting of two interconnected teams under mPIs and a Project Director-an Administration and Leadership Team, and a Data Management and Analysis Team. This structure leverages RTI multidisciplinary experts and will provide ReVAMPP Centers, NIAID, and stakeholders centralized administrative, communication, and operational support for Network-wide activities, while also establishing data sharing and analysis standards and platforms. The Specific Aims of the RTI-based CDSC align with these two teams and will use both established and novel innovative approaches and technologies to (Aim 1) coordinate preparatory vaccine and antibody strategy research by establishing and maintaining ReVAMPP Network governance, administration, and communication; and (Aim 2) accelerate transparent collaborative vaccine and antibody strategy research by developing and maintaining a secure ReVAMPP Network Private Portal that includes centralized resource, data sharing, and reporting systems. This independent, but integrated team of administrators, communicators, and data science experts embedded within the ReVAMPP Network as the CDSC, will coordinate, facilitate, and empower Network investigators and NIAID to proactively prepare to rapidly share information with key stakeholders across the globe when new viral pandemic/outbreaks occur.